CDC Immunization Committee Charter Rescinded
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 41 minutes ago
0mins
Should l Buy MRNA?
Source: seekingalpha
- Charter Rescission Reason: The HHS announced the rescission of the CDC's Advisory Committee on Immunization Practices charter due to an administrative error in meeting revised public notification timing requirements under the Federal Advisory Committee Act, necessitating the re-establishment of the committee and highlighting management failures.
- Committee Member Changes: In June 2025, HHS Secretary Robert F. Kennedy Jr. dismissed all 17 committee members at the time and replaced them with his chosen individuals with minimal scrutiny, raising concerns about the transparency of the committee's operations.
- Court Ruling Impact: A federal judge's stay in March 2023 on the appointment of Kennedy's 13 new ACIP members and the proposed changes to the childhood vaccination schedule illustrates the tension between political and public health policies.
- Complex Political Context: The Trump administration has appealed this ruling, reflecting the contentious nature of current vaccination policies and their potential impact on public health, while also underscoring the significant role of political factors in healthcare decision-making.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MRNA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MRNA
Wall Street analysts forecast MRNA stock price to fall
20 Analyst Rating
1 Buy
16 Hold
3 Sell
Hold
Current: 49.040
Low
17.00
Averages
32.47
High
63.00
Current: 49.040
Low
17.00
Averages
32.47
High
63.00
About MRNA
Moderna, Inc. is a biotechnology company advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is engaged in developing medicines across infectious disease vaccines, oncology therapeutics and rare disease therapeutics. Its platform incorporates advances across three components, mRNA, delivery, and the manufacturing process, to advance its medicines. Its products are Spikevax and mNEXSPIKE (its COVID vaccines), and mRESVIA (its vaccine against respiratory syncytial virus (RSV)). It also has a diverse development pipeline that consists of 35 therapeutic and vaccine programs, six of which are in late-stage development. It has regulatory filings under review for its seasonal flu+COVID vaccine (mRNA-1083) in Europe and Canada and for its seasonal flu vaccine (mRNA-1010) in the United States, Europe, Canada and Australia. Its rare disease programs are Propionic acidemia (mRNA-3927); Methylmalonic acidemia (mRNA-3705), and Cystic Fibrosis (mRNA-3692/VX-522).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CDC Immunization Committee Charter Rescinded
- Charter Rescission Reason: The HHS announced the rescission of the CDC's Advisory Committee on Immunization Practices charter due to an administrative error in meeting revised public notification timing requirements under the Federal Advisory Committee Act, necessitating the re-establishment of the committee and highlighting management failures.
- Committee Member Changes: In June 2025, HHS Secretary Robert F. Kennedy Jr. dismissed all 17 committee members at the time and replaced them with his chosen individuals with minimal scrutiny, raising concerns about the transparency of the committee's operations.
- Court Ruling Impact: A federal judge's stay in March 2023 on the appointment of Kennedy's 13 new ACIP members and the proposed changes to the childhood vaccination schedule illustrates the tension between political and public health policies.
- Complex Political Context: The Trump administration has appealed this ruling, reflecting the contentious nature of current vaccination policies and their potential impact on public health, while also underscoring the significant role of political factors in healthcare decision-making.
See More
Anti-Vaccine Bills Fail Amid Public Health Advocacy
- Anti-Vaccine Bill Failures: Dozens of anti-vaccine bills backed by the 'Make America Healthy Again' coalition have failed, indicating limited political power among supporters and showcasing the effectiveness of public health advocacy.
- Public Support for Vaccination: A February poll revealed that a bipartisan majority of Americans favor school vaccination mandates and view vaccines as safe for children, which has hindered the progress of anti-vaccine legislation in several states.
- Legislative Dynamics Shift: Despite a surge in anti-vaccine bills, particularly in states like Idaho and West Virginia, none have passed, underscoring the prioritization of public health policies over anti-vaccine initiatives.
- Future Legislative Expectations: Both public health advocates and anti-vaccine proponents anticipate ongoing debates over vaccine policies in state legislatures, suggesting that the influence of the anti-vaccine movement is rising and may lead to more proposed legislation.
See More
Biologics Sector Rapidly Emerging as Growth Leader
- Biologics Innovation: HCW Biologics is advancing HCW9302, a first-in-class IL-2 fusion protein targeting autoimmune diseases, with preliminary clinical data expected in the first half of 2026, potentially improving patient tolerability and reducing side effects.
- Massive Market Potential: Totaligent's planned acquisition of Aetherium Medical aims to connect biologics companies with APAC healthcare networks, with projections indicating the global medical tourism market could approach $274 billion by 2032, led by Asia-Pacific growth.
- Integration of Technologies: The convergence of biologics and artificial intelligence is accelerating drug development, with Moderna's mRNA platform demonstrating how programmable biologic therapies can be developed at unprecedented speed, establishing itself as an industry benchmark.
- Optimized Regulatory Environment: Japan's fast-track approval framework allows conditional commercialization of regenerative medicine and cell therapies, significantly shortening time-to-market and attracting substantial investor interest.
See More
Hantavirus Outbreak Raises Public Health Concerns
- Outbreak Overview: As of Tuesday, the WHO reported 11 cases linked to the hantavirus outbreak, with 9 confirmed cases including 3 deaths; while no positive cases have been found in the U.S., public concern is rising significantly.
- Monitoring Measures: In the U.S., 18 individuals are being monitored across Nebraska and Atlanta for potential exposure, and although more cases may emerge, experts assert that the risk remains low due to the hantavirus's limited transmissibility.
- CDC Response Capability: While the CDC appears to have the outbreak under control, experts warn that past cuts to the agency and the withdrawal from the WHO may undermine the U.S.'s ability to respond to future infectious disease threats, especially against more contagious pathogens.
- Vaccine Development Progress: Moderna's shares surged approximately 12% after confirming it is researching a potential vaccine for hantavirus, although specific treatments are still years away, this development may provide hope for future public health responses.
See More
Cruise Ship Hantavirus Outbreak Raises Concerns
- Outbreak Overview: As of Tuesday, the WHO reported 11 cases linked to the cruise ship hantavirus outbreak, with 9 confirmed cases including 3 deaths, although no positive cases have been found in the U.S., indicating a potential threat.
- Public Health Risk: While the risk of hantavirus transmission is low, primarily spread through contact with infected wild rodents, experts warn that the cruise ship environment may exacerbate the risk of virus transmission, especially in confined spaces.
- CDC Response Capability: Experts point out that the CDC's delayed response to the outbreak, coupled with a lack of effective leadership and resources, may hinder the U.S.'s ability to respond to future infectious disease threats, particularly after staffing cuts and strained relations with the WHO.
- Future Outbreak Preparedness: Public health experts emphasize that the current outbreak exposes vulnerabilities in the U.S. public health infrastructure, calling for a restoration of the CDC's expertise and resources to effectively respond to potentially more transmissible pathogens in the future.
See More
FDA Commissioner's Departure Triggers Biotech Market Reactions
- Leadership Change: The departure of FDA Commissioner Marty Makary is perceived as a positive signal for the biotech sector, although analysts warn that the industry may face pressure until a permanent replacement is found, potentially leading to market volatility.
- Market Reaction: The Nasdaq biotechnology index rose 1% on Tuesday, reflecting an initial positive response from investors to Makary's exit, particularly following his public disagreements with drugmakers like Replimune and Moderna.
- Increased Uncertainty: Analysts caution that the ongoing leadership vacuum at the FDA could result in more delays and unpredictability, diminishing the agency's ability to provide guidance and credible policy commitments, thereby impacting the investability of the biopharma ecosystem.
- Stock Performance: Shares of uniQure and Replimune rose by 5% and nearly 10%, respectively, indicating market optimism regarding new leadership, although Makary's departure also introduces uncertainty within the industry.
See More
CDC Immunization Committee Charter Rescinded
- Charter Rescission Reason: The HHS announced the rescission of the CDC's Advisory Committee on Immunization Practices charter due to an administrative error in meeting revised public notification timing requirements under the Federal Advisory Committee Act, necessitating the re-establishment of the committee and highlighting management failures.
- Committee Member Changes: In June 2025, HHS Secretary Robert F. Kennedy Jr. dismissed all 17 committee members at the time and replaced them with his chosen individuals with minimal scrutiny, raising concerns about the transparency of the committee's operations.
- Court Ruling Impact: A federal judge's stay in March 2023 on the appointment of Kennedy's 13 new ACIP members and the proposed changes to the childhood vaccination schedule illustrates the tension between political and public health policies.
- Complex Political Context: The Trump administration has appealed this ruling, reflecting the contentious nature of current vaccination policies and their potential impact on public health, while also underscoring the significant role of political factors in healthcare decision-making.
See More
Anti-Vaccine Bills Fail Amid Public Health Advocacy
- Anti-Vaccine Bill Failures: Dozens of anti-vaccine bills backed by the 'Make America Healthy Again' coalition have failed, indicating limited political power among supporters and showcasing the effectiveness of public health advocacy.
- Public Support for Vaccination: A February poll revealed that a bipartisan majority of Americans favor school vaccination mandates and view vaccines as safe for children, which has hindered the progress of anti-vaccine legislation in several states.
- Legislative Dynamics Shift: Despite a surge in anti-vaccine bills, particularly in states like Idaho and West Virginia, none have passed, underscoring the prioritization of public health policies over anti-vaccine initiatives.
- Future Legislative Expectations: Both public health advocates and anti-vaccine proponents anticipate ongoing debates over vaccine policies in state legislatures, suggesting that the influence of the anti-vaccine movement is rising and may lead to more proposed legislation.
See More
Biologics Sector Rapidly Emerging as Growth Leader
- Biologics Innovation: HCW Biologics is advancing HCW9302, a first-in-class IL-2 fusion protein targeting autoimmune diseases, with preliminary clinical data expected in the first half of 2026, potentially improving patient tolerability and reducing side effects.
- Massive Market Potential: Totaligent's planned acquisition of Aetherium Medical aims to connect biologics companies with APAC healthcare networks, with projections indicating the global medical tourism market could approach $274 billion by 2032, led by Asia-Pacific growth.
- Integration of Technologies: The convergence of biologics and artificial intelligence is accelerating drug development, with Moderna's mRNA platform demonstrating how programmable biologic therapies can be developed at unprecedented speed, establishing itself as an industry benchmark.
- Optimized Regulatory Environment: Japan's fast-track approval framework allows conditional commercialization of regenerative medicine and cell therapies, significantly shortening time-to-market and attracting substantial investor interest.
See More
Hantavirus Outbreak Raises Public Health Concerns
- Outbreak Overview: As of Tuesday, the WHO reported 11 cases linked to the hantavirus outbreak, with 9 confirmed cases including 3 deaths; while no positive cases have been found in the U.S., public concern is rising significantly.
- Monitoring Measures: In the U.S., 18 individuals are being monitored across Nebraska and Atlanta for potential exposure, and although more cases may emerge, experts assert that the risk remains low due to the hantavirus's limited transmissibility.
- CDC Response Capability: While the CDC appears to have the outbreak under control, experts warn that past cuts to the agency and the withdrawal from the WHO may undermine the U.S.'s ability to respond to future infectious disease threats, especially against more contagious pathogens.
- Vaccine Development Progress: Moderna's shares surged approximately 12% after confirming it is researching a potential vaccine for hantavirus, although specific treatments are still years away, this development may provide hope for future public health responses.
See More
Cruise Ship Hantavirus Outbreak Raises Concerns
- Outbreak Overview: As of Tuesday, the WHO reported 11 cases linked to the cruise ship hantavirus outbreak, with 9 confirmed cases including 3 deaths, although no positive cases have been found in the U.S., indicating a potential threat.
- Public Health Risk: While the risk of hantavirus transmission is low, primarily spread through contact with infected wild rodents, experts warn that the cruise ship environment may exacerbate the risk of virus transmission, especially in confined spaces.
- CDC Response Capability: Experts point out that the CDC's delayed response to the outbreak, coupled with a lack of effective leadership and resources, may hinder the U.S.'s ability to respond to future infectious disease threats, particularly after staffing cuts and strained relations with the WHO.
- Future Outbreak Preparedness: Public health experts emphasize that the current outbreak exposes vulnerabilities in the U.S. public health infrastructure, calling for a restoration of the CDC's expertise and resources to effectively respond to potentially more transmissible pathogens in the future.
See More
FDA Commissioner's Departure Triggers Biotech Market Reactions
- Leadership Change: The departure of FDA Commissioner Marty Makary is perceived as a positive signal for the biotech sector, although analysts warn that the industry may face pressure until a permanent replacement is found, potentially leading to market volatility.
- Market Reaction: The Nasdaq biotechnology index rose 1% on Tuesday, reflecting an initial positive response from investors to Makary's exit, particularly following his public disagreements with drugmakers like Replimune and Moderna.
- Increased Uncertainty: Analysts caution that the ongoing leadership vacuum at the FDA could result in more delays and unpredictability, diminishing the agency's ability to provide guidance and credible policy commitments, thereby impacting the investability of the biopharma ecosystem.
- Stock Performance: Shares of uniQure and Replimune rose by 5% and nearly 10%, respectively, indicating market optimism regarding new leadership, although Makary's departure also introduces uncertainty within the industry.
See More
